June 13 (Reuters) - U.S. drug developer Flex Pharma Inc said on Wednesday it plans to reduce its workforce by 60 percent, as part of a restructuring, and was ending certain ongoing mid-stage trials.
The company will now focus on developing its Amyotrophic lateral sclerosis (ALS) drug, FLX-787, the company's lead product candidate, for dysphagia or difficulty in swallowing. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
In his 2016 letter to Berkshire Hathaway shareholders, legendary investor Warren Buffett wrote, “Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold. When downpours of that sort occur, it’s imperative that we ...
Microsoft reported better than anticipated Q3 earnings on Thursday, powered by growth in its cloud products.
On paper, Mark Zuckerberg is Meta’s lowest-paid employee, with a $1 dollar salary and no bonus.
Car-rental operator Hertz reported it lost another $200 million due to its EV gamble.
(Bloomberg) -- Four months into office, Argentine President Javier Milei has pulled off a critical feat in a country long ravaged by runaway inflation: He stabilized the currency.Most Read from BloombergUS Economy Slows and Inflation Jumps, Damping Soft-Landing HopesMalaysia in Talks With Tycoons on Casino to Revive $100 Billion Forest CityJavier Milei Fuels Wild Rally That Makes Peso No. 1 in WorldBig Tech Surges in Late Hours on Blowout Earnings: Markets WrapBiden’s Gains Against Trump Vanish
Intel reported its Q1 earnings on Thursday, beating analysts' estimates. But a disappointing outlook sent shares sliding.
Google stock soared after parent Alphabet reported first-quarter earnings and revenue that handily beat consensus estimates.
Alphabet reported Q1 earnings on Thursday that beat estimates. The company also announced its first-ever dividend.
Tesla's loss of $328.3 billion this year in stock value certainly hurts. But it's only the second-largest market value loss in the S&P 500.